Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 5:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 843 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo equivalent Clear all

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Insulin like growth factor, type 1, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 19
States / cities: Scottsdale, Arizona • San Francisco, California • Jacksonville, Florida + 16 more

Conditions: Traumatic Brain Injury
Interventions: Premarin IV, Placebo; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 50 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 2
States / cities: Dallas, Texas

Conditions: Preeclampsia, Gestational Hypertension
Interventions: spironolactone 25 mg orally once daily, Placebo tablet to match spironolactone; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 3
States / cities: Boston, Massachusetts • Pittsburgh, Pennsylvania

Conditions: Staphylococcal Infection
Interventions: Trimethoprim-sulfamethoxazole, Placebo, Clindamycin; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Months to 85 Years
Enrollment: 1,310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 6
States / cities: San Francisco, California • Torrance, California • Atlanta, Georgia + 3 more

Conditions: Biliary Tract Cancer, Metastatic Cancer, Advanced Cancer
Interventions: Ramucirumab, Merestinib, Cisplatin, Gemcitabine, Placebo Oral, Placebo IV; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 309 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 13
States / cities: Tucson, Arizona • San Francisco, California • Washington D.C., District of Columbia + 7 more

Conditions: Autistic Disorder
Interventions: citalopram hydrobromide, placebo; Drug · Other
Lead sponsor: Boston University; Other
Eligibility: 5 Years to 17 Years
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 6
States / cities: Los Angeles, California • New Haven, Connecticut • Lebanon, New Hampshire + 3 more

Conditions: Alopecia Areata
Interventions: Ritlecitinib 100 mg, Ritlecitinib 50 mg, Placebo - 100 mg, Placebo - 50 mg; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Enrollment: 674 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 60
States / cities: Birmingham, Alabama • Hot Springs, Arkansas • Brea, California + 39 more

Conditions: End Stage Renal Disease
Interventions: Ergocalciferol, Placebo; Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Heart Failure
Interventions: LCZ696, valsartan, LCZ696 placebo, valsartan placebo; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 365 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 38
States / cities: Beverly Hills, California • Sacramento, California • San Diego, California + 28 more

Conditions: Crohn's Disease, Fatigue
Interventions: L-carnitine, Placebo; Drug · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Obesity
Interventions: Saxenda®, Placebo; Drug · Other
Lead sponsor: Texas Tech University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: Lubbock, Texas

Conditions: Alcohol Use Disorder, Insomnia
Interventions: Daridorexant, Placebo, Brief Counseling, MEMS and Medication Accounting, Contingency Management for Medication Adherence; Drug · Behavioral · Device
Lead sponsor: Sterling McPherson; Other
Eligibility: 18 Years and older
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Spokane, Washington

Conditions: COVID-19 Lower Respiratory Infection, SARS-CoV2 Infection
Interventions: Osteopathic Manipulative Therapy; Other
Lead sponsor: Ohio University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Dublin, Ohio

Conditions: Bupivacaine, Pain, Postoperative
Interventions: Bupivacaine, Liposomal bupivacaine, Placebos; Drug
Lead sponsor: Brooke Army Medical Center; Federal
Eligibility: 18 Years and older · Female only
Enrollment: 132 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Fort Sam Houston, Texas

Conditions: Depression
Interventions: Org 24448, Placebo; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 21 Years to 70 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 2
States / cities: Bethesda, Maryland • New York, New York

Conditions: Osteoarthritis, Knee, Osteoarthritis of the Knee
Interventions: Placebo, Cannabidiol (CBD), Tetrahydrocannabinol (Marinol® or generic equivalent (e.g., dronabinol); Drug
Lead sponsor: Steven E Harte, PhD; Other
Eligibility: 21 Years to 75 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Postoperative Depression
Interventions: Ketamine, Normal saline; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Obstructive Sleep Apnea
Interventions: IHL-42X Low Dose, IHL-42X High Dose, Placebo, IHL-42X (Optimal Dose), Dronabinol, Acetazolamide; Drug
Lead sponsor: Incannex Healthcare Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 20
States / cities: Chula Vista, California • Long Beach, California • Upland, California + 16 more

Conditions: Diphtheria, Hepatitis B, Poliomyelitis, Pertussis, Tetanus
Interventions: DTaP-Hep B-IPV Vaccine, Monovalent Hep B Vaccine, Placebo; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Up to 5 Days
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Torrance, California

Conditions: Niemann-Pick Disease, Type C
Interventions: arimoclomol, Placebo; Drug
Lead sponsor: ZevraDenmark; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 2
States / cities: Oakland, California • Rochester, Minnesota

Conditions: Apnea of Prematurity
Interventions: Caffeine Citrate, Placebo; Drug
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: 29 Weeks to 33 Weeks
Enrollment: 827 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 16
States / cities: Birmingham, Alabama • Palo Alto, California • Atlanta, Georgia + 12 more

Conditions: Malaria, Malaria, Cerebral
Interventions: Intravenous Artesunate, Placebo; Drug
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 55 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Any Ear Nose or Throat Conditions, With Identified Need for a Diagnostic Procedure or Surgery on or Through the Mucous Membranes of the Nasal Cavities
Interventions: Cocaine HCl 4% Topical Solution, Cocaine HCl 10% Topical Solution, Placebo Topical Solution; Drug
Lead sponsor: Lannett Company, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 646 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Retinopathy of Prematurity, Bronchopulmonary Dysplasia (BPD)
Interventions: Inositol lower volume, Inositol mid-level volume, Inositol high volume, Placebo low volume; Drug
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: 12 Hours to 72 Hours
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 17
States / cities: Birmingham, Alabama • Palo Alto, California • New Haven, Connecticut + 13 more

Search by objective public record fields.

Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial

Resuscitative Endocrinology:Single-dose Clinical Uses for Estrogen-Traumatic Brain Injury

Spironolactone to Improve Pregnancy-Associated Hypertension Trajectories

Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus

A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer

Citalopram for Children With Autism and Repetitive Behavior (STAART Study 1)

A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata

DIVINE: Dialysis Infection and Vitamin D In New England

EntrestoTM (LCZ696) In Advanced Heart Failure (LIFE Study)

L-carnitine to Treat Fatigue Associated With Crohn's Disease

To Predict Weight Loss Response to Liraglutide (Saxenda®), From fMRI-based Determination of Food Cue Reactivity

Daridorexant for People With Insomnia and Alcohol Use Disorder Study

Osteopathic Manipulative Therapy Effects on Prolonged Post-COVID Olfactory Dysfunction

Wound Infiltration of Liposomal Bupivacaine v Plain Bupivacaine for Post-Op Pain Control in Elective Cesarean Delivery

Org 24448 to Treat Major Depression

Cannabinoid Interactions With Central and Peripheral Pain Mechanisms in Osteoarthritis of the Knee

Ketamine for Postoperative Avoidance of Depressive Symptoms: The K-PASS Feasibility Trial

RePOSA-Revealing the Efficacy of IHL-42X Use in Patients With OSA

Pentavalent DTaP-Hep B-IPV

Arimoclomol Prospective Study in Participants Diagnosed With Niemann-Pick Disease Type C

Moderately Preterm Infants With Caffeine at Home for Apnea (MoCHA) Trial

Study of the Safety of Intravenous Artesunate

Topical Application of Cocaine HCl 4%, or 10%, or Placebo Solution in Local (Topical) Anesthesia

Multi-dose Pharmacokinetics and Dose Ranging of Inositol in Premature Infants (INS-2)